ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,301,691 | -23.1% | 92,615 | -0.5% | 0.00% | -20.0% |
| Q2 2023 | $4,291,796 | +132649.6% | 93,037 | +15.4% | 0.01% | +25.0% |
| Q1 2023 | $3,233 | -8.1% | 80,631 | +6.2% | 0.00% | -20.0% |
| Q4 2022 | $3,519 | -99.9% | 75,953 | +3.6% | 0.01% | 0.0% |
| Q3 2022 | $3,035,000 | -28.7% | 73,291 | +2.7% | 0.01% | -16.7% |
| Q2 2022 | $4,259,000 | -11.9% | 71,394 | +7.3% | 0.01% | 0.0% |
| Q1 2022 | $4,833,000 | -18.7% | 66,554 | -5.8% | 0.01% | -14.3% |
| Q4 2021 | $5,941,000 | -6.2% | 70,646 | +0.6% | 0.01% | -22.2% |
| Q3 2021 | $6,332,000 | -7.8% | 70,210 | -2.6% | 0.01% | 0.0% |
| Q2 2021 | $6,870,000 | -22.5% | 72,049 | -7.4% | 0.01% | -25.0% |
| Q1 2021 | $8,861,000 | -24.9% | 77,827 | -8.7% | 0.01% | -25.0% |
| Q4 2020 | $11,795,000 | +85.5% | 85,203 | +10.1% | 0.02% | +60.0% |
| Q3 2020 | $6,360,000 | -12.3% | 77,385 | -16.5% | 0.01% | -16.7% |
| Q2 2020 | $7,251,000 | +90.9% | 92,705 | +8.4% | 0.01% | +50.0% |
| Q1 2020 | $3,799,000 | +5.8% | 85,508 | +1.7% | 0.01% | +33.3% |
| Q4 2019 | $3,590,000 | +4.1% | 84,050 | +4.2% | 0.01% | 0.0% |
| Q3 2019 | $3,449,000 | -33.8% | 80,631 | -1.7% | 0.01% | -40.0% |
| Q2 2019 | $5,207,000 | +0.3% | 81,995 | +9.6% | 0.01% | 0.0% |
| Q1 2019 | $5,189,000 | +82.0% | 74,817 | +14.1% | 0.01% | +66.7% |
| Q4 2018 | $2,851,000 | -12.2% | 65,561 | +54.2% | 0.01% | 0.0% |
| Q3 2018 | $3,246,000 | -6.1% | 42,520 | -5.5% | 0.01% | -14.3% |
| Q2 2018 | $3,457,000 | +65.0% | 44,974 | +9.5% | 0.01% | +75.0% |
| Q1 2018 | $2,095,000 | +17.0% | 41,083 | +6.5% | 0.00% | 0.0% |
| Q4 2017 | $1,790,000 | -27.4% | 38,586 | -16.6% | 0.00% | -20.0% |
| Q3 2017 | $2,466,000 | -12.6% | 46,293 | +2.0% | 0.01% | -16.7% |
| Q2 2017 | $2,820,000 | -9.4% | 45,404 | -1.1% | 0.01% | -14.3% |
| Q1 2017 | $3,112,000 | +6.3% | 45,906 | +10.3% | 0.01% | 0.0% |
| Q4 2016 | $2,927,000 | +2.0% | 41,628 | +2.9% | 0.01% | -12.5% |
| Q3 2016 | $2,869,000 | +49.6% | 40,445 | +3.1% | 0.01% | +33.3% |
| Q2 2016 | $1,918,000 | -22.9% | 39,221 | -0.2% | 0.01% | -25.0% |
| Q1 2016 | $2,487,000 | -43.3% | 39,286 | +0.4% | 0.01% | -42.9% |
| Q4 2015 | $4,388,000 | +27.1% | 39,116 | +9.1% | 0.01% | +16.7% |
| Q3 2015 | $3,453,000 | +9.6% | 35,850 | +16.5% | 0.01% | +20.0% |
| Q2 2015 | $3,151,000 | +681.9% | 30,774 | +374.6% | 0.01% | +900.0% |
| Q1 2015 | $403,000 | +74.5% | 6,484 | +23.3% | 0.00% | 0.0% |
| Q4 2014 | $231,000 | -22.5% | 5,259 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $298,000 | +31.9% | 5,259 | +4.3% | 0.00% | 0.0% |
| Q2 2014 | $226,000 | – | 5,044 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |